Wednesday 11 November 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
1
Average plausibility
75%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
01HealthGlobal

Medicine-access leader warns weight-loss drug boom could put insulin supply at risk

The Access to Medicine Foundation warns that drugmakers’ focus on obesity treatments could weaken attention to insulin, especially where diabetes care is already hard to obtain.

The Guardian reports that the head of the Access to Medicine Foundation warned that the rush into GLP-1 drugs, used for diabetes and weight loss, risks drawing pharmaceutical companies’ attention away from insulin. Its excerpt contrasts the spread of products such as Ozempic and Mounjaro with difficulties obtaining basic diabetes treatment in poorer countries. Unbiased Headlines and Traders Union also describe the foundation’s warning, but their accounts do not establish that the weight-loss boom has already reduced insulin supplies.

What holds up

  • ✓The supplied coverage consistently supports that the foundation issued a warning about insulin access. Unbiased Headlines and Traders Union identify its chief executive, Jay Iyer, as the person raising the concern.
  • ✓The Guardian describes existing barriers to basic diabetes treatment in poorer countries. Traders Union also reports precarious insulin access, although neither excerpt supplies country-level measurements.

What doesn't yet

  • ?The central uncertainty is cause and effect: none of the cited excerpts provides production records, delivery figures, or other evidence showing that investment in weight-loss drugs has reduced insulin supply.
  • ?Only a few newsrooms are represented in the cited coverage, and other accounts may be missing. These reports repeat the same foundation warning rather than provide separate checks of insulin supply; the supplied snippets are not full-article verification.

Ask before you share

  • →Have manufacturers reduced insulin production or deliveries, and do records connect any reductions to investment in weight-loss drugs?
  • →Which countries and insulin products face shortages, and how much do price, distribution, or purchasing problems explain poor access?
  • →What do insulin manufacturers and health authorities say about the foundation’s warning and plans to protect supply?

Sources & original reporting

  1. [1]The Guardian · Published 10 Nov 2026 · theguardian.com
  2. [2]Unbiasedheadlines · Published 10 Nov 2026 · unbiasedheadlines.com
  3. [3]Tradersunion · Published 10 Nov 2026 · tradersunion.com